There are two types of variant agreements, one for bipartisan cooperation agreements and the other for multi-party consortium agreements. These agreements can be used if a new party joins the project. One of the fundamental principles of all types of agreements is that no amendment to the agreement is valid unless all existing parties agree to the change in writing. Both models are available for download from the ARMA Brunswick Agreements website. Standard agreements are starting points and their use is not mandatory. Each model agreement provides for different circumstances and is not sectoral, allowing for flexible use. However, model agreements can be adapted to the particular circumstances of your project. Comments on the Lambert toolbox and your experience of using the models are welcome. NIHR wants to ensure that the research it supports is conducted in an environment that promotes maximum dissemination and, if necessary, exploitation of results. It is therefore essential that NIHR know who is involved in the research and how this relationship is regulated.
In this context, contractors should be aware that NIHR may wish to review all cooperation agreements before being implemented to ensure that they are in compliance with the NIHR research contract. The standard research contract requires organizations to disclose agreements with third parties and to ensure that no agreement is reached to prevent organizations from complying with contractual terms. The model is available to all universities and other public research institutes, not just those in the Brunswick group. The institutions that have registered for use are: This agreement is not intended to be used between universities and commercial organizations. An MTA human tissue model was created as part of the Brunswick Group initiative. Nationally approved standard agreements help speed up the NHS trial allocation process, as there is no longer a need for site-by-site audits and local legal agreements. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly. The decision guide is intended only for the use of bilateral cooperation agreements in the field of research. There is no decision guide for the 4 consortium agreements.